2.5 Outcome definitions
Our composite end-point outcomes consisted of the incidence of DSA, chronic lung allograft dysfunction (CLAD), and mortality. Serum samples were routinely collected post-transplantation to screen for the presence of anti-human leukocyte antigen (HLA) antibodies. The presence of DSA was determined by comparing the measured HLA types with donor HLA typing. CLAD was defined as a 20% decline from the best post-transplant FEV1 according to the International Society of Heart and Lung Transplant Guidelines.20 Additionally, we examined the distribution characteristics of TAC exposure, represented by average C0 and IPV, across 3 distinct time periods (0–3 months, 3–12 months and 12–24 months).